Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Nvidia Dumped Recursion Pharmaceuticals Stock. Should You?

When artificial intelligence (AI) chip maker NVIDIA Corporation (NVDA) heads for the exit, investors instinctively glance at the door. In its latest 13F filing, the chip giant disclosed that it had completely exited its position in the AI-driven drug developer Recursion Pharmaceuticals (RXRX).

At the end of Q3 2025, Nvidia held 7.71 million shares. The stake represented a modest slice of its expansive, meticulously managed AI portfolio. Still, the headline carried weight. Traders pushed the stock down as much as 14% during the session before buyers regrouped and lifted it to a nearly 2% gain by the close of Wednesday, Feb 18.

Fundamentals

See More
  • Market Capitalization, $K 1,835,028
  • Shares Outstanding, K 519,838
  • Annual Sales, $ 58,840 K
  • Annual Income, $ -463,660 K
  • EBIT $ -724 M
  • EBITDA $ -687 M
  • 60-Month Beta 0.95
  • Price/Sales 32.61
  • Price/Cash Flow N/A
  • Price/Book 1.63

Options Overview Details

View History
  • Implied Volatility 129.58% (+37.19%)
  • Historical Volatility 69.36%
  • IV Percentile 88%
  • IV Rank 38.85%
  • IV High 222.65% on 01/14/26
  • IV Low 70.45% on 08/06/25
  • Expected Move (DTE 8) 0.36 (9.60%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 12,038
  • Volume Avg (30-Day) 18,485
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 378,284
  • Open Int (30-Day) 338,060
  • Expected Range 3.36 to 4.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.21
  • Low Estimate -0.41
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +47.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.98 +24.83%
on 02/18/26
5.24 -29.01%
on 01/22/26
-0.95 (-20.34%)
since 01/16/26
3-Month
2.98 +24.83%
on 02/18/26
5.24 -29.01%
on 01/22/26
-0.31 (-7.69%)
since 11/19/25
52-Week
2.98 +24.83%
on 02/18/26
10.87 -65.78%
on 02/20/25
-7.15 (-65.78%)
since 02/19/25

Most Recent Stories

More News
Nvidia Dumped Recursion Pharmaceuticals Stock. Should You?

Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk or opportunity?

NVDA : 187.90 (-0.04%)
RXRX : 3.72 (+5.38%)
ARKK : 72.24 (+1.19%)
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business...

RXRX : 3.72 (+5.38%)
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026,...

RXRX : 3.72 (+5.38%)
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President,...

RXRX : 3.72 (+5.38%)
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here?

Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

ARKG : 29.87 (+0.71%)
RXRX : 3.72 (+5.38%)
ARKK : 72.24 (+1.19%)
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November...

ONCY : 1.0000 (-1.96%)
SANA : 4.14 (+5.34%)
ABSI : 2.78 (+2.96%)
RXRX : 3.72 (+5.38%)
TEM : 59.96 (+6.77%)
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks...

RXRX : 3.72 (+5.38%)
AI-Powered Platforms Accelerate Healthcare's Preventative Care Wellness Revolution

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – The artificial intelligence in healthcare market is projected to expand from $17.2 billion in 2025 to $77.2 billion...

AIDX.TO : 0.62 (unch)
HWAIF : 0.4530 (-3.82%)
WELL.TO : 3.96 (+0.76%)
RXRX : 3.72 (+5.38%)
TEM : 59.96 (+6.77%)
WHTCF : 2.8800 (+0.35%)
ALEN-U.CN : 1.2100 (unch)
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a...

RXRX : 3.72 (+5.38%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

AVAI : 0.3972 (-0.70%)
ANVS : 2.41 (-0.82%)
RXRX : 3.72 (+5.38%)
ZYME : 23.32 (+1.79%)
NTLA : 13.04 (+4.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 4.11
2nd Resistance Point 3.92
1st Resistance Point 3.82
Last Price 3.72
1st Support Level 3.53
2nd Support Level 3.34
3rd Support Level 3.24

See More

52-Week High 10.87
Fibonacci 61.8% 7.86
Fibonacci 50% 6.93
Fibonacci 38.2% 5.99
Last Price 3.72
52-Week Low 2.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar